In human AIS, the treatment goal by GPVI blockade would be mitigation of I/R injury (driven by thrombo-inflammation) after EVT contributing to up to 40% of the final stroke volume despite successful recanalization.47,48. This evidence concerns the gene GP6 and Stroke.